In line with its recent marketing push, Tetra Bio-Pharma Inc., has named a new VP Marketing.
Tapping Steeve Neron’s deep roots in the pharmaceutical industry is another sign that Tetra’s going hard on its multiple initiatives e.g. pain and inflammation Tetra Bio-Pharma plans aggressive marketing effort for pain & inflammation products and its recent FDA submission Tetra moves deeper into US; targets rare cancers & eye disease in FDA submissions.
Mr. Neron’s 32 years of experience spans numerous therapeutic sectors including cardiology, rheumatology, endocrinology, women’s health, asthma/COPD, OTC and dermatology
Prior to joining Tetra Bio-Pharma he held a senior marketing position at Bausch Health Canada, formerly Valeant.
Executive Vice-President, Commercial Operations Richard Giguere said that Mr. Neron’s. vast experience “will enable Tetra to achieve its high standards in executional excellence.”
Mr. Neron said that: “Tetra has set the bar high from a clinical development standpoint and this is a critical factor to maximize the therapeutic potential of cannabis.”
TBP was trading at $1.17 this morning – up 6% on half a million shares.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers.
The company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements.
It is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.